{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:04:31Z","timestamp":1773212671516,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11940-004-0012-9","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T19:34:15Z","timestamp":1180985655000},"page":"201-207","source":"Crossref","is-referenced-by-count":16,"title":["Dementia in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"6","author":[{"given":"Karen E.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/089198878800100106","volume":"1","author":"JL Cummings","year":"1988","unstructured":"Cummings JL: Intellectual impairment in Parkinson\u2019s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988, 1:24\u201336.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","volume":"56","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Andersen K, Larsen JP, et al.: Risk of dementia in Parkinson\u2019s disease: a community based prospective study. Neurology 2001, 56:730\u2013736. This is a well-designed study of community-dwelling patients that sheds light on how cognition is affected in higher functioning individuals with PD.","journal-title":"Neurology"},{"key":"12_CR3","first-page":"3","volume-title":"Parkinson\u2019s Disease in the Older Patient","author":"JV Hindle","year":"2001","unstructured":"Hindle JV: Dementia in PD. In Parkinson\u2019s Disease in the Older Patient. Edited by Payfer JR, Hindle JV. London: Arnold Press; 2001:3\u2013117."},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1212\/01.WNL.0000031426.21683.E2","volume":"59","author":"J Green","year":"2002","unstructured":"Green J, McDonald WM, Vitek JL, et al.: Cognitive impairments in advanced PD without dementia. Neurology 2002, 59:1320\u20131324.","journal-title":"Neurology"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ana.10219","volume":"51","author":"G Levy","year":"2002","unstructured":"Levy G, Schupf N, Tang M-X, et al.: Combined effect of age and severity on the risk of dementia in Parkinson\u2019s disease. Ann Neurol 2002, 51:722\u2013729. This is a population-based cohort study of 180 PD patients that looks at incident dementia. This is the first study to longitudinally examine the effects of risk factors for dementia in PD. The combined effect of two commonly cited risk factors for dementia in PD, age and severity of extrapyramidal symptoms, was examined.","journal-title":"Ann Neurol"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.10086","volume":"17","author":"G Levy","year":"2002","unstructured":"Levy G: Do risk factors for Alzheimer\u2019s disease predict dementia in Parkinson\u2019s disease? An exploratory study. Mov Disord 2002, 17:250\u2013257.","journal-title":"Mov Disord"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/jnnp.74.7.852","volume":"74","author":"C Colosimo","year":"2003","unstructured":"Colosimo C, Hughes AJ, Kilford L, Lees AJ: Lewy body cortical involvement may not always predict dementia in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2003, 74:852\u2013856.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/mds.10581","volume":"18","author":"E Murat","year":"2003","unstructured":"Murat E: What causes mental dysfunction in Parkinson\u2019s Disease? Mov Disord 2003, 18(suppl):S63-S71.","journal-title":"Mov Disord"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/WNL.54.2.407","volume":"54","author":"P Tiraboschi","year":"2000","unstructured":"Tiraboschi P, Hansen LA, Alford M, et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407\u2013411.","journal-title":"Neurology"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000, 356:2031\u20132036.","journal-title":"Lancet"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp.61.3.324-a","volume":"61","author":"M Hutchinson","year":"1996","unstructured":"Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1996, 61:324\u2013326.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","volume":"72","author":"D Aarsland","year":"2002","unstructured":"Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson\u2019s disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002, 72:708\u2013712. This is a controlled study with crossover design involving 14 PD patients. Cognition was shown to improve with donepezil, and motor symptoms did not worsen.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s007020100008","volume":"108","author":"EA Werber","year":"2001","unstructured":"Werber EA, Rabey JM: The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson\u2019s disease and dementia. J Neural Transm 2001, 108:1319\u20131325.","journal-title":"J Neural Transm"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0891988703256054","volume":"16","author":"A Kurita","year":"2003","unstructured":"Kurita A, Ochiai Y, Kono Y, et al.: The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson\u2019s disease. J Geriatr Psychiatry Neurol 2003, 16:184\u2013188.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2002","unstructured":"Fabbrini G, Barbanti P, Aurilia C, et al.: Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease. Neurol Sci 2002, 23:41\u201343.","journal-title":"Neurol Sci"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"PJ Reading","year":"2001","unstructured":"Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001, 16:1171\u20131174.","journal-title":"Mov Disord"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","volume":"18","author":"R Bullock","year":"2002","unstructured":"Bullock R, Cameron A: Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson\u2019s disease: a case series. Curr Med Res Opin 2002, 18:258\u2013264.","journal-title":"Curr Med Res Opin"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Hutchinson M, Larsen JP: Cognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia. Int J Geriatr Psychiatry 2003, 18:937\u2013941.","journal-title":"Int J Geriatr Psychiatry"},{"key":"12_CR19","first-page":"273","volume":"22","author":"M Merello","year":"1999","unstructured":"Merello M, Nouzeilles MI, Cammarota A, Leiguarda R: Effect of memantine (NMDA antagonist) on Parkinson\u2019s disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999, 22:273\u2013276. This is a study with crossover design assessing memantine in 12 PD patients. Cognition was not addressed, but effects of memantine on motor function in PD were examined.","journal-title":"Clin Neuropharmacol"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/mds.870050308","volume":"5","author":"M Sano","year":"1990","unstructured":"Sano M, Stern Y, Marder K, et al.: A controlled trial of piracetam in intellectually impaired patients with Parkinson disease. Mov Disord 1990, 5:230\u2013234.","journal-title":"Mov Disord"},{"key":"12_CR21","first-page":"1235","volume":"317","author":"E Furigeld","year":"1989","unstructured":"Furigeld E, Gaggen M, Nedwick P, et al.: Double-blind study with phosphatidylserine in parkinsonian patients with senile dementia of the Alzheimer\u2019s type (SDAT). Prog Clin Biol Res 1989, 317:1235\u20131246.","journal-title":"Prog Clin Biol Res"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/WNL.44.9.1756","volume":"44","author":"K Kieburtz","year":"1994","unstructured":"Kieburtz K: The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson\u2019s disease. Parkinson Study Group. Neurology 1994, 44:1756\u20131759.","journal-title":"Neurology"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870130112","volume":"13","author":"I Shoulson","year":"1998","unstructured":"Shoulson I: Where do we stand on neuroprotection? Where do we go from here? Mov Disord 1998, 13(suppl):46\u201348.","journal-title":"Mov Disord"},{"issue":"suppl","key":"12_CR24","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1002\/ana.10484","volume":"53","author":"K Kieburtz","year":"2003","unstructured":"Kieburtz K: Designing neuroprotection trials in Parkinson\u2019s disease. Ann Neurol 2003, 53(suppl):S100-S107.","journal-title":"Ann Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-004-0012-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-004-0012-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-004-0012-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:03:57Z","timestamp":1683867837000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-004-0012-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11940-004-0012-9","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}